In CRC and hepatocellular carcinoma (HCC), promoter hypermethylation of CLDN3 is correlated with decreased claudin-3 expression, but promoter derepression leads to upregulation in prostate and ovarian cancers (25, 139, 140). Here, CLDN3 is linked to ovarian cancer.